1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
| Autor: | Felip, E., Srivastava, M., Reck, M., Wakelee, H., Altorki, N.K., Vallieres, E., Liersch, R., Harada, M., Tanaka, H., Hamm, J.T., McCune, S., Bennett, E., Gitlitz, B.J., McNally, V.A., Novello, S., Ballinger, M., Zou, W., Nabet, B., Das Thakur, M., Zhou, C. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2022 16 Supplement 1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|